Amhealer

Description

The drug is identified by SPL code 34089-3 and is presented as a white to off-white, round, biconvex tablet, which is debossed with "A" on one side and "1" on the other. Each tablet contains 1 mg of the active ingredient. The formulation includes inactive ingredients such as lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, magnesium stearate, and color additives. The tablets are packaged in bottles containing 30 units.

Uses and Indications

This drug is indicated for administration via a spray mechanism. The user should open the container cap and press the spray button 1 to 2 times to deliver the intended dose.

There are no specified teratogenic or nonteratogenic effects associated with this drug.

Dosage and Administration

The recommended dosage for the medication is a maximum of 5 mL per day, which should not exceed 50 doses. Healthcare professionals are advised to ensure that the total daily dosage does not surpass this limit to maintain safety and efficacy.

Administration should be performed according to the prescribed route, ensuring proper technique is followed to optimize therapeutic outcomes. It is essential to monitor the patient’s response to the medication and adjust the dosage as necessary, while remaining within the established maximum limits.

Contraindications

There are no contraindications listed for the use of this product. It is important to evaluate each patient's individual circumstances and medical history when considering treatment options.

Warnings and Precautions

It is imperative to keep this product out of reach of babies and children to prevent accidental ingestion or misuse. Additionally, the product should be stored away from direct sunlight to maintain its efficacy and stability.

Currently, there are no specific general precautions or laboratory tests outlined for the safe use of this product. Healthcare professionals are advised to remain vigilant and monitor for any adverse effects or unusual reactions in patients.

In the event of an emergency, it is crucial to seek immediate medical assistance. Should any concerning symptoms arise, patients should discontinue use and consult their healthcare provider for further guidance.

Side Effects

Patients should be advised to keep the product out of reach of babies and children to prevent accidental ingestion or exposure. Additionally, it is important to store the product away from direct sunlight to maintain its efficacy and safety. No specific adverse reactions have been reported in clinical trials or postmarketing experiences beyond these warnings.

Drug Interactions

No specific drug interactions have been identified for this medication. Additionally, there are no reported interactions with laboratory tests. Therefore, no dosage adjustments or monitoring recommendations are necessary based on drug or laboratory test interactions.

Packaging & NDC

Below are the non-prescription pack sizes of Amhealer (sodium fluoride). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients should be monitored closely, as the medication must be kept out of reach of babies and children to prevent accidental ingestion. It is essential for healthcare professionals to educate caregivers on the importance of proper storage to ensure safety in pediatric populations.

Geriatric Use

There is no specific information regarding the use of this medication in geriatric patients, including dosage adjustments, safety concerns, or special precautions. Healthcare providers should exercise caution when prescribing this medication to elderly patients, as individual responses may vary. Monitoring for potential adverse effects and therapeutic efficacy is recommended in this population.

Pregnancy

There is no specific information regarding the use of this medication during pregnancy, including safety concerns, dosage modifications, or special precautions. Healthcare professionals should consider the lack of data when prescribing this medication to pregnant patients. It is advisable to weigh the potential benefits against any unknown risks to fetal outcomes. Women of childbearing potential should be counseled on the importance of effective contraception during treatment and the need to inform their healthcare provider if they become pregnant or plan to become pregnant while on this medication.

Lactation

There is no specific information available regarding the use of this medication in nursing mothers or its effects on lactation. Consequently, healthcare professionals should exercise caution when prescribing this medication to lactating mothers, as the potential risks to breastfed infants are not well characterized. It is advisable to consider the benefits of breastfeeding alongside the potential risks associated with the medication.

Renal Impairment

There is no specific information regarding dosage adjustments, special monitoring, or safety considerations for patients with renal impairment. Healthcare professionals should exercise caution when prescribing to patients with reduced kidney function, as the absence of detailed guidance necessitates careful clinical judgment. Regular monitoring of renal function may be advisable in these patients to ensure safety and efficacy.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

In the absence of specific information regarding overdosage, healthcare professionals are advised to exercise caution and adhere to general principles of management in cases of suspected overdose.

It is essential to monitor the patient closely for any potential symptoms that may arise from an overdose. Symptoms can vary widely depending on the substance involved and the individual patient's response.

In the event of an overdose, immediate medical attention should be sought. Healthcare providers should implement supportive care measures, which may include monitoring vital signs, providing symptomatic treatment, and ensuring the patient's safety.

If available, consultation with a poison control center or a medical toxicologist is recommended to guide the management of the overdose effectively.

Documentation of the incident, including the substance involved, the amount taken, and the time of ingestion, is crucial for appropriate treatment and follow-up care.

Nonclinical Toxicology

No relevant information is available regarding teratogenic or non-teratogenic effects. Additionally, there is no pertinent data concerning nonclinical toxicology or animal pharmacology and toxicology.

Postmarketing Experience

No postmarketing experience details are available in the insert text.

Patient Counseling

Healthcare providers should advise patients to keep this medication out of reach of babies and children to prevent accidental ingestion or misuse. It is important to emphasize the potential risks associated with exposure to this medication in young children. Patients should be informed about the necessity of storing the medication in a secure location, away from areas accessible to children, to ensure their safety.

Storage and Handling

The product is supplied in various package configurations, with specific NDC numbers available for identification. It is essential to store the product in a manner that protects it from direct sunlight to maintain its integrity and efficacy.

For optimal storage conditions, it is recommended to keep the product in a cool, dry place, away from sources of heat and moisture. Special handling precautions should be observed to ensure that the product remains within the specified temperature range and is not exposed to adverse environmental conditions.

Additional Clinical Information

The medication is administered orally, with a recommended maximum dosage of five units per day, equating to a total of 50 units. There are no additional details available regarding laboratory tests, abuse information, patient counseling, or postmarketing experience.

Drug Information (PDF)

This file contains official product information for Amhealer, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)